Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
17 July 2024 - 10:50PM
Business Wire
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Chief
Medical Officer Merdad Parsey, MD, PhD, will leave the company
early next year. While the company works to identify a successor,
Dr. Parsey will continue as Chief Medical Officer until the first
quarter of 2025 and support this transition over the next several
months.
“On behalf of everyone at Gilead, I want to thank Merdad for his
significant contributions as our Chief Medical Officer over the
last five years. These were pivotal years for the company as we
worked to strengthen and diversify the portfolio, and Merdad played
a fundamental role in our success,” said Daniel O’Day, Chairman and
Chief Executive Officer, Gilead. “We have more than doubled our
portfolio under Merdad’s leadership, and with 54 ongoing clinical
trials across virology, oncology, and inflammation, we are well
positioned to build on our success for the future.”
Dr. Parsey joined Gilead in November 2019 and is responsible for
overseeing the company’s global clinical development and medical
affairs organizations. During his tenure, he led the growth of the
development organization, specifically with the advancement of
market leading treatments in virology and the establishment of
Gilead’s oncology pipeline and therapeutics.
“It has been a privilege to lead the development team,
especially as we have worked to deliver transformative medicines
for people with HIV, COVID-19, and cancer,” said Dr. Parsey. “I am
profoundly excited about the work we have done to build a strong,
diverse clinical pipeline that has tremendous potential to deliver
on our commitment to improve health for people around the
world.”
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has
pursued and achieved breakthroughs in medicine for more than three
decades, with the goal of creating a healthier world for all
people. The company is committed to advancing innovative medicines
to prevent and treat life-threatening diseases, including HIV,
viral hepatitis, COVID-19, and cancer. Gilead operates in more than
35 countries worldwide, with headquarters in Foster City,
Calif.
Forward-Looking
Statement
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks, uncertainties and other factors,
including the risk that Dr. Parsey may leave prior to the currently
anticipated timeline; challenges that Gilead may encounter in
identifying a successor to Dr. Parsey; and any assumptions
underlying any of the foregoing. These and other risks,
uncertainties and factors are described in detail in Gilead’s
Quarterly Report on Form 10-Q for the quarter ended March 31, 2024,
as filed with the U.S. Securities and Exchange Commission. These
risks, uncertainties and other factors could cause actual results
to differ materially from those referred to in the forward-looking
statements. All statements other than statements of historical fact
are statements that could be deemed forward-looking statements. The
reader is cautioned that any such forward-looking statements are
not guarantees of future performance and involve risks and
uncertainties and is cautioned not to place undue reliance on these
forward-looking statements. All forward-looking statements are
based on information currently available to Gilead, and Gilead
assumes no obligation and disclaims any intent to update any such
forward-looking statements.
For more information about Gilead, please visit
the company’s website at www.gilead.com, follow Gilead on X/Twitter
(@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716867026/en/
Ashleigh Koss, Media public_affairs@gilead.com Jacquie Ross,
Investors investor_relations@gilead.com
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024